spacer
home > epc > autumn 2003 > eea - an overview of requirements impacting industry
PUBLICATIONS
European Pharmaceutical Contractor

EEA - An Overview of Requirements Impacting Industry

Pharmacovigilance requirements in the EU are laid down in a variety of different documents, applicable according to the status and route of authorisation (such as pre- or post-approval, centrally or nationally approved). As it can be difficult for experienced personnel in this field, yet alone a newcomer, to digest these overlapping and detailed requirements, this article provides an overview of the reporting requirements applicable to the Marketing Authorisation Holder (MAH); gives sources for further information; and reviews possible changes arising as part of the current legislative review and as the EU moves towards enlargement.

The Basic Framework

Pharmacovigilance requirements in the EU are laid down in EU Regulations (540/95 (1) and 2309/93 (2), EU Directives 65/65 (3), 75/319 (4), 2000/38 (5) and 2001/83 (6)) and EU Guidelines (for example Notice to Marketing Authorisation Holders: Volume 9 - Pharmacovigilance Guidelines (7). There are also several policy papers relating to more specific functions, for example the concept paper on monitoring compliance (CPMP (Committee for Proprietary Medicinal Products) /PhVWP (Pharmacovigilance Working Party)/1618/01 (8)) and the EMEA (European Medicines Evaluation Agency) policy paper on electronic transmission (EMEA/H/5255/01 (9)). In addition, the EU Clinical Trials Directive (2001/20/EC (10)) lays down the basis for reporting from the clinical study environment, with relevant guidances currently being finalised.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Margaret Walters, Director of Pharmacovigilance at Merck Sharp & Dohme

Margaret Walters is currently Director of the European Office of Pharmacovigilance for Merck Sharp & Dohme Ltd. She has more than 16 years' experience in many areas of pharmacovigilance along with a further 10 years in basic research at Wellcome. Margaret is a member of the EFPIA Pharmacovigilance Ad Hoc group, co-chairs the PhRMA (EU) Pharmacovigilance team, is active in the EMEA/EFPIA Joint Working Party on Electronic Submissions and was part of the original (pre-ICH) MCA MedDRA Working Party.

She is also the author of several papers and her academic links include acting as External Adviser to the Postgraduate Diploma in Pharmacovigilance at the University of Hertfordshire.

spacer
Margaret Walters
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new market reference added to Safe’n’Sound®, our passive safety device platform

Safe’n’Sound® is on the market in Europe with a newly registered injectable medication. The commercial launch of HULIO™ (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018. Hulio™, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®.
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs

Bioclinica

With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement